Gaurav Singh Gulsin
University of Leicester1 paperORCID 0000-0002-1740-9270OpenAlex
Papers
Diabetes, Obesity & MetabolismHumans
GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
In patients with chronic kidney disease, adding a GLP-1 receptor agonist was associated with fewer major adverse kidney events (HR 0.70) than SGLT2…In patients with chronic kidney disease, adding a GLP-1 receptor agonist was associated with fewer major adverse kidney events (HR 0.70) than SGLT2 inhibitors alone.